Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744430 · ClinicalTrials.gov registry record · Phase 2
Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain
A Phase 2 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02744430 is a Phase 2 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 33 participants.
The verdict
NCT02744430, a Phase 2 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT (Computed Tomography) scan-proven ureteral stone between 4 to 10 mm undergoing expectant management.
Interventions
- OTHER Placebo
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-07-22 |
| Est. Completion | 2019-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744430
The ClinicalTrials.gov registry entry for NCT02744430 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02744430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02744430 about?
NCT02744430 is a clinical study titled "Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain". The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT (Computed Tomography) scan-proven ureteral stone between 4 to 10 mm undergoing expectant management.
What is the current status of trial NCT02744430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-07-22. Estimated completion is 2019-10-31.
What interventions are being tested in trial NCT02744430?
The interventions under investigation include: Placebo (OTHER), Mirabegron (DRUG).
Who is sponsoring clinical trial NCT02744430?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.